Compare Eli Lilly And Co (LLY) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Eli Lilly And Co trades at $1,163.24 (market cap $1.02T), while YieldMax NVDA Option Income Strategy ETF trades at $12.5. The key difference: Eli Lilly And Co pays a 0.6% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| LLY | NVDY | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.24K | $17.96 |
52-Week Low | $625.65 | $12.03 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
NVDY trades at $12.41, up 0.4% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The fund generates weekly dividends, with recent payouts ranging from $0.10 to $0.21 per share. News coverage highlights the trade-off between income and potential upside capture relative to NVIDIA's stock performance.
The outlook hinges on investor preference for consistent income versus capital appreciation. Risks include underperformance versus NVIDIA during strong rallies and fee drag. Sentiment is mixed, with some questioning the strategy's long-term value amid NVIDIA's volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
